Measures · D12 in 2018 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Medication Adherence for Hypertension (RAS antagonists)
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- Percent of plan members with a prescription for a blood pressure medication who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication. One of the most important ways people with high blood pressure can manage their health is by taking medication as directed. The plan, the doctor, and the member can work together to do this. (“Blood pressure medication” means an ACE (angiotensin converting enzyme) inhibitor, an ARB (angiotensin receptor blocker), or a direct renin inhibitor drug.
- How it's calculated
- This measure is defined as the percent of Medicare Part D beneficiaries 18 years and older who adhere to their prescribed drug therapy for renin angiotensin system (RAS) antagonists: angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or direct renin inhibitor medications. This percentage is calculated as the number of member-years of enrolled beneficiaries 18 years and older with a proportion of days covered (PDC) at 80 percent or higher for RAS antagonist medications during the measurement period (numerator) divided by the number of member-years of enrolled beneficiaries 18 years and older with at least two blood pressure medications fills on unique dates of service during the measurement period (denominator). The PDC is the percent of days in the measurement period “covered” by prescription claims for the same medication or another in its therapeutic category. Beneficiaries with ESRD coverage dates or that received one or more prescriptions for sacubitril/valsartan anytime during the measurement period are excluded. Beneficiaries are only included in the measure calculation if the first fill of their medication occurs at least 91 days before the end of the enrollment period. The Part D Medication Adherence measure is adapted from the Medication Adherence- Proportion of Days Covered measure that was developed and endorsed by the (Last Updated 03/27/2018) DRAFT Page 70 DRAFT DRAFT Pharmacy Quality Alliance (PQA). The PDC Adherence measures are also endorsed by the National Quality Forum (NQF). See the medication list for this measure. The Part D Medication Adherence rate is calculated using the National Drug Code (NDC) list and obsolete NDC date methodology maintained by the PQA. The complete NDC list is posted along with these technical notes. NDCs with obsolete dates are included in the measure calculation if the obsolete dates as reported by PQA are within the period of measurement (measurement year) or within six months prior to the beginning of the measurement year.
- Data source
- Prescription Drug Event (PDE) data The data for this measure come from PDE data files submitted by drug plans to Medicare by June 30, 2017 with dates of service from January 1, 2016-December 31, 2016. Only final action PDE claims are used to calculate this measure. PDE claims are limited to members who received at least two prescriptions on unique dates of service for RAS antagonist medication(s). PDE adjustments made post-reconciliation are not reflected in this measure. Additional data sources include the Common Medicare Environment (CME), the Medicare Enrollment Database (EDB), and the Common Working File (CWF). • CME is used for enrollment information. • EDB is used for hospice enrollment and ESRD status (using the ESRD indicator). • CWF is used to identify inpatient stays for PDPs and MA-PDs, and skilled nursing facility stays for PDPs.
- Measurement period
- 01/01/2016 – 12/31/2016
- Better when
- Higher
- Weight
- 3 (Intermediate Outcome Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- —
- In improvement measure
- Yes
- Used in CAI
- Yes
- Exclusions
Show
Contracts with 30 or fewer enrolled member-years (in the denominator)- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the medication or NDC lists, are excluded from CMS analyses. Also, the member-years of enrollment adjustment is made by CMS to account for partial enrollment within the benefit year. Enrollment is measured at the episode level, and inclusion in the measure is determined separately for each episode – i.e., to be included for a given episode, the beneficiary must meet the initial inclusion criteria for the measure during that episode. The measure is weighted based on the total number of member years for each episode in which the beneficiary meets the measure criteria. For instance, if a beneficiary is enrolled for a three-month episode, disenrolled for a six-month episode, reenrolled for a three-month episode, and meets the measure criteria during each enrollment episode, s/he will count as 0.5 member years in the rate calculation (3/12 + 3/12 = 6/12). The PDC calculation is adjusted for overlapping prescriptions for the same drug which is defined by active ingredient at the generic name level using the Medi-Span generic ingredient name. The calculation also adjusts for Part D beneficiaries’ stays in inpatient (IP) settings, hospice enrollments, and stays in skilled nursing facilities (SNFs). The SNF adjustment only applies to PDPs because SNF data are not currently available for MA-PDs. Please see Attachment L: Medication Adherence Measure Calculations for more information about these calculation adjustments. When available, beneficiary death date from the CME is the end date of a beneficiary’s measurement period.
From the 2018 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 84 | 85 | +1 |
| 3★ | MA-PD | 88 | 89 | +1 |
| 4★ | MA-PD | 90 | 91 | +1 |
| 5★ | MA-PD | 93 | 94 | +1 |
| 2★ | PDP | 87 | 88 | +1 |
| 3★ | PDP | 89 | 90 | +1 |
| 4★ | PDP | 90 | 91 | +1 |
| 5★ | PDP | 92 | 92 | 0 |
2018 star distribution
Not rated: Plan too new to be measured (83); No data available (52); Plan not required to report measure (15); Not enough data available (9)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 90 % | >= 90 % to < 93 % | >= 93 % |
| 2027 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2026 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2026 | PDP | < 88 % | >= 88 % to < 90 % | >= 90 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2025 | MA-PD | < 83 % | >= 83 % to < 87 % | >= 87 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2025 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2024 | MA-PD | < 82 % | >= 82 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2024 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 94 % | >= 94 % |
| 2023 | MA-PD | < 78 % | >= 78 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2023 | PDP | < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 96 % | >= 96 % |
| 2022 | MA-PD | < 74 % | >= 74 % to < 82 % | >= 82 % to < 87 % | >= 87 % to < 90 % | >= 90 % |
| 2022 | PDP | < 85 % | >= 85 % to < 88 % | >= 88 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2021 | MA-PD | < 80 % | >= 80 % to < 84 % | >= 84 % to < 87 % | >= 87 % to < 89 % | >= 89 % |
| 2021 | PDP | < 84 % | >= 84 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 90 % | >= 90 % |
| 2020 | MA-PD | < 80% | ? 80% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2020 | PDP | < 83% | ? 83% to < 85% | ? 85% to < 88% | ? 88% to < 90% | ? 90% |
| 2019 | MA-PD | < 79% | ? 79% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2019 | PDP | < 84% | ? 84% to < 86% | ? 86% to < 87% | ? 87% to < 89% | ? 89% |
| 2018 | MA-PD | < 74% | ? 74% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2018 | PDP | < 78% | ? 78% to < 83% | ? 83% to < 86% | ? 86% to < 89% | ? 89% |
| 2017 | MA-PD | < 71% | ? 71% to < 75% | ? 75% to < 79% | ? 79% to < 83% | ? 83% |
| 2017 | PDP | < 77% | ? 77% to < 80% | ? 80% to < 83% | ? 83% to < 85% | ? 85% |
| 2016 | MA-PD | < 58% | ? 58% to < 73% | ? 73% to < 77% | ? 77% to < 81% | ? 81% |
| 2016 | PDP | < 76% | ? 76% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2015 | MA-PD | < 72% | ? 72% to < 76% | ? 76% to < 81% | ? 81% to < 85% | ? 85% |
| 2015 | PDP | < 72% | ? 72% to < 76% | ? 76% to < 81% | ? 81% to < 84% | ? 84% |
Lowest-scoring contracts, 2018
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| S5588 Paramount Prescription Drug Plan | MEDICAL MUTUAL OF OHIO | — | 73 | 1 | −2 | 13 | 0% |
| H8170 America's 1st Choice Of South Carolina, Inc. | Anthem Inc. | — | 67 | 1 | 0 | 15 | 0% |
| H5810 Molina Healthcare of California | Molina Healthcare, Inc. | 1,500 | 68 | 1 | −1 | 14 | 0% |
| H0908 Wellcare | Centene Corporation | 8,453 | 69 | 1 | −1 | 13 | 0% |
| H0174 Wellcare | Centene Corporation | 50,506 | 69 | 1 | — | 13 | 0% |
| H6988 Anthem Blue Cross and Blue Shield HP | Elevance Health, Inc. | 10,164 | 70 | 1 | 0 | 12 | 1% |
| H5587 Blue Cross Blue Shield of Arizona Health Choice | Blue Cross Blue Shield of Arizona | 8,603 | 71 | 1 | 0 | 11 | 1% |
| H0490 Molina Healthcare Of Ohio, Inc. | Molina Healthcare, Inc., | — | 71 | 1 | 0 | 11 | 1% |
| H8266 Constellation Health, Llc. | Constellation Health, LLC. | — | 71 | 1 | 0 | 11 | 1% |
| H7200 Amerigroup Tennessee, Inc. | Anthem Inc. | — | 71 | 1 | −1 | 11 | 1% |
| S0522 Symphonix Health Insurance, Inc. | UnitedHealth Group, Inc. | — | 75 | 1 | 0 | 11 | 2% |
| S4802 Wellcare | Centene Corporation | 9,042,365 | 75 | 1 | −1 | 11 | 2% |
| H9190 Gateway Health Plan Of Ohio, Inc. | Gateway Health Plan, LP | — | 72 | 1 | −1 | 10 | 2% |
| H9730 Wellcare | Centene Corporation | 35,990 | 72 | 1 | 0 | 10 | 2% |
| H9082 Molina Healthcare of New Mexico, Inc. | Molina Healthcare, Inc., | — | 72 | 1 | −2 | 10 | 2% |
| H2879 Molina Healthcare of Wisconsin and Massachusetts | Molina Healthcare, Inc. | — | 72 | 1 | −1 | 10 | 2% |
| H1112 Wellcare | Centene Corporation | 25,885 | 72 | 1 | 0 | 10 | 2% |
| H5746 Amerigroup Community Care of New Mexico | Elevance Health, Inc. | — | 73 | 1 | −2 | 9 | 3% |
| H1587 Arkansas Superior Select Health Plans | Select Founders, LLC | 2,833 | 73 | 1 | — | 9 | 3% |
| H2400 Abilis Health (HMO SNP) | BrightSpring Health Services, Inc. | 1,139 | 74 | 2 | — | 8 | 4% |
| H3928 Aetna Medicare | CVS Health Corporation | 4,912 | 74 | 2 | −1 | 8 | 4% |
| H3708 American Health Advantage of Oklahoma | Mitchell Family Office | 549 | 74 | 2 | −2 | 8 | 4% |
| H1264 Wellcare Of Texas, Inc. | WellCare Health Plans, Inc. | — | 74 | 2 | 0 | 8 | 4% |
| H5576 Vantage Health Plan | Louisiana Health Service & Indemnity Company | — | 74 | 2 | 0 | 8 | 4% |
| H4227 VISTA Health Plan Inc. | Independence Health Group, Inc. | 23,267 | 74 | 2 | 0 | 8 | 4% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2025 – 12/31/2025 | 3 | Prescription Drug Events |
| 2026 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2024 – 12/31/2024 | 3 | Prescription Drug Events |
| 2025 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2023 – 12/31/2023 | 3 | Prescription Drug Events |
| 2024 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2022 – 12/31/2022 | 3 | Prescription Drug Events |
| 2023 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2021 – 12/31/2021 | 3 | Prescription Drug Events |
| 2022 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2018 – 12/31/2018 | 3 | Prescription Drug Events |
| 2019 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2017 – 12/31/2017 | 3 | Prescription Drug Events |
| 2018 | D12 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2016 – 12/31/2016 | 3 | Prescription Drug Events |
| 2017 | D13 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2015 - 12/31/2015 | 3 | Prescription Drug Events |
| 2016 | D13 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2014 - 12/31/2014 | 3 | Prescription Drug Events |
| 2015 | D12 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2013 - 12/31/2013 | 3 | Prescription Drug Events |